Skip to content cialis drug contraindications

Leadership Team

Jeffrey Leathe, CEO & Chairman, Lantos Technologies

Jeffrey Leathe was most recently the Chief Executive Officer and Chairman of the Board at Biocius Life Sciences, a venture backed company involved in developing high throughput instrumentation for mass spectrometry applications in pharmaceutical drug discovery that was acquired by Agilent Technologies. Previously, Mr. Leathe served as the Senior Vice President and Chief Financial Officer of BioTrove Inc., and as Executive Vice President, Chief Financial Officer and Treasurer for Apogent Technologies from 1990-2003.

Mr. Leathe is a director and chairman of the audit committee for Bottomline Technologies, a NASDAQ-listed software firm. He received his MBA from the University of North Carolina, Chapel Hill, his B.S. from the University of New Hampshire and holds his CPA. Watch Technology TV’s interview with Lantos CEO Jeffrey Leathe.

Gary St. Pierre, Vice President and Chief Financial Officer

Gary St. Pierre has held senior finance executive positions in both large public and small private companies, most recently the Chief Financial Officer for Biocius Life Sciences, Inc.  Previously, Mr.  St. Pierre held senior financial executive positions at BioTrove, Inc., Pelican Life Sciences, Axcelis Technologies and Apogent Technologies.

Mr. St. Pierre has a bachelor’s degree in Economics from Dartmouth College and an Executive MBA from the University of New Hampshire.

Lora Allemeier, Chief Commercial Officer

Ms. Allemeier has held senior level global product development, strategic planning, and marketing roles with pharmaceutical and medical device companies. Most recently, she was Head of Global Marketing and Head of Global Regulatory Affairs for Cochlear, based in Sydney, Australia, where she had extensive experience in working with audiologists, ENTs and the hearing market to develop and launch new products globally, including in emerging markets. Previously, she held a variety of senior level marketing, business development, product development and program management positions at GlaxoSmithKline, Stryker, and Eli Lilly, as well as the start-up GMP Companies.

Ms. Allemeier received her MBA from the Indiana University Kelley School of Business and her bachelor’s degree from the Johns Hopkins University.

Dr. Brian Fligor, Chief Audiology Officer

Prior to joining Lantos Technologies, Dr. Fligor was Director of Diagnostic Audiology at Boston Children’s Hospital and Assistant Professor at Harvard Medical School.  He is also an instructor at Northeastern University’s Au.D. Program and Salus University ’s International Au.D. Bridge Program.  Dr. Fligor’s publications describing factors associated with hearing loss from medical interventions have helped shape recommendations by the Joint Committee on Infant Hearing Position Statement (2007) and proposed new ototoxicity grading scales for children with cancer who are treated with chemotherapy

Dr. Fligor received his B.S. in Biomedical Engineering and Sc.D. in Audiology from Boston University.  Renowned for his research in hearing prevention from noise, music and invasive medical treatments, Dr. Fligor has extensive experience fitting hearing aids, ear plugs and monitors for children, adults and musicians. He is a founder and past-chair of the Music-induced Hearing Disorders taskforce for the National Hearing Conservation Association.